Rob Hart

Rob Hart began their career in 2007 as a Partner at Telegraph Hill Partners. In 2010, they became a Director at MedPricer.com, a spend management software for hospitals which was later acquired by Premier, Inc. In 2015, they became Co-Founding Investor, Former CFO and Director at Akoya Biosciences, Inc., a spatial biology and high parameter tissue analysis company, which went public in 2021. In 2016, they became a Director at TrakCel Ltd. In 2017, they became a Director at Verogen and Aquaro Biosystems. In 2019, they became a Director at Nimble Therapeutics, Invisalert Solutions, Inc., and Secretary and Board Observer at Specific Diagnostics, a rapid antibiotic susceptibility testing company which was later acquired by bioMérieux S. A. In 2020, they became a Director at Nivagen Pharmaceuticals, Inc.

Rob Hart completed their education history with a Chartered Financial Analyst certification from the CFA Institute in January 2001. Rob then obtained a Master of Business Administration (M.B.A.) and a Doctor of Law (J.D.) from Northwestern University's Kellogg School of Management and Pritzker School of Law, respectively, in 2004. Prior to that, they obtained a Bachelor of Science (B.S.) / Bachelor of Arts (B.A.) in Geology / Economics from UC Santa Barbara in 1995. Rob began their educational journey at Mira Loma High School, a public school.